Integra LifeSciences earnings per share fell 2.4% annually while revenue grew 5×

Yahoo Finance··Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Integra LifeSciences saw its earnings per share fall by 2.4% annually while its revenue grew 5× over the past five years, signaling that incremental sales were much less profitable. The company also showed no organic revenue growth over the past two years, suggesting it may need acquisitions to expand. Its net-debt-to-EBITDA ratio indicates overleverage, raising the risk of shareholder dilution. Integra LifeSciences trades at a forward P/E of 7.2× with a stock price of $17.87.

Impact on assets 3

Biotech & Genomic Medicine▼ · 1 stocks
Integra LifeSciences Holdings
IART
▼ NegativeCapitalrelevance

Earnings per share fell 2.4% annually, no organic revenue growth, overleveraged, and low P/E indicates financial weakness.

Energy▲ · 1 stocks
Defense & Geopolitical Fragmentation▲ · 1 stocks
© 2026 MarketIVNews